Tillomed Laboratories, a subsidiary of Emcure Pharmaceuticals (NSE:EMCURE, BOM:544210) has agreed to acquire the product portfolio of UK-based Manx Healthcare and its subsidiaries Manx Pharma and Manx Generics for 19.7 million pounds sterling, according to a Friday filing to the Indian stock exchanges.
Tillomed will acquire Manx's product portfolio including intellectual properties and relevant stocks.
Under the agreement, a payment of 6.2 million pounds sterling will be made upfront, and the remaining will be through milestone payments over the next 18 months.
Shares of the company were down nearly 4% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.